Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark's subsidiary Ichnos Glenmark Innovation (IGI) announced a new drug development candidate, ISB 2301, a first-in-class multispecific antibody that activates both T cells and NK cells to target solid tumors. The drug targets three tumor-associated antigens simultaneously and was developed using IGI's proprietary BEAT® technology platform. Preclinical studies in non-human primates showed excellent pharmacokinetics, tolerability, and a favorable safety profile. IGI plans to file an Investigational New Drug (IND) application by end of 2026 and begin clinical studies in 2027. The announcement notes that IGI's prior asset ISB 2001 attracted a collaboration with AbbVie, validating their platform.
This is a positive R&D milestone for Glenmark, showcasing innovation from its biotech subsidiary. However, the drug is still years away from commercialization with no immediate revenue impact. The validation of the BEAT® platform through the AbbVie partnership adds credibility but remains a long-term value driver.